Last reviewed · How we verify
NCT03544983
Genetic Education in BRCA Families
NA trial testing Web + Streamlined Telephone Genetic Information in BRCA1 Mutation in 240 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Georgetown University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 240 |
| Start date | 1 May 2020 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Web + Streamlined Telephone Genetic Information
Conditions studied
- BRCA1 Mutation — all drugs for BRCA1 Mutation →
- BRCA2 Mutation — all drugs for BRCA2 Mutation →
Sponsor
Georgetown University
Who can join
Adults 21 to 75, any sex, with BRCA1 Mutation or BRCA2 Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary goal of this research is to test a web-based genetic education intervention that is designed to educate men and women from hereditary cancer families about the personal relevance of genetic testing in order to help them male decisions about whether to pursue genetic testing. We will test this intervention against standard care for men and women from hereditary cancer families. The web-based educational intervention includes all of the information typically covered during genetic counseling. As a result, after completing the education intervention, participants can proceed directly to a brief telephone call with a genetic counselor followed by testing if they choose. A baseline survey will be administered prior to randomization and then follow-up surveys will be administered at 1-month and 6-months post-randomization. Primary outcomes will be completion of genetic counseling, uptake of genetic testing, genetic test results and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03544983
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for BRCA1 Mutation
Currently open trials in the same condition.
- NCT06972719 — Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy · NA · recruiting
- NCT07253051 — BRCA Mutation Carriers' Platform a Multicenter Study · recruiting
- NCT06201234 — Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+ · Phase 2 · recruiting
- NCT06488378 — Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Brea · Phase 1 · recruiting
- NCT05485766 — Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer · Phase 2 · recruiting
Other Georgetown University trials
Trials by the same sponsor.
- NCT07228000 — Bundled Cancer Screening and Genetic Services Navigation · NA · not yet recruiting
- NCT07128927 — Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors · NA · recruiting
- NCT06046287 — Daratumumab for Polyneuropathy Associated With MGUS · Phase 2 · withdrawn
- NCT06980103 — Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyro · NA · recruiting
- NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03544983 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Georgetown University
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03544983.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing